Business Context and Reporting Period
Liquidia Corporation (LQDA) is a biopharmaceutical company focused on respiratory and vascular diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company reported for the fiscal quarter ended March 31, 2026. Its primary revenue driver is YUTREPIA (treprostinil) inhalation powder, which received FDA approval in May 2025 and began commercialization in June 2025. The company also generates service revenue through a promotion agreement with Sandoz regarding generic treprostinil injection.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $132.9 million | $3.1 million |
| Product Sales (Net) | $129.9 million | $0 |
| Service Revenue (Net) | $3.0 million | $3.1 million |
| Net Income (Loss) | $52.9 million | $(38.4) million |
| Operating Income (Loss) | $61.5 million | $(35.4) million |
| Diluted EPS | $0.52 | $(0.45) |
| Cash and Cash Equivalents | $222.8 million | $190.7 million (Dec 31, 2025) |
| Long-Term Debt (Total) | $177.9 million | $191.3 million (Dec 31, 2025) |
| Operating Cash Flow | $53.0 million | $(30.7) million |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by 4,158% year-over-year, driven entirely by the commercial launch of YUTREPIA, which generated $129.9 million in product sales compared to zero in the prior year.
- Profitability Turnaround: The company transitioned from a net loss of $38.4 million in Q1 2025 to a net income of $52.9 million in Q1 2026. Operating income improved by $96.9 million.
- Expense Growth: Selling, general, and administrative (SG&A) expenses rose 56% to $46.9 million, and R&D expenses increased 80% to $12.6 million, reflecting commercialization ramp-up and clinical trial activities for the L606 candidate.
- Cash Position: Cash and cash equivalents increased by $32.1 million during the quarter, supported by strong operating cash flows of $53.0 million.
Guidance, Outlook, Risks, and Contingencies
Outlook and Liquidity: Management believes it has sufficient cash to meet obligations and minimum cash covenants for at least the next twelve months. The company expects to continue incurring significant expenses to commercialize YUTREPIA and advance the L606 pipeline. Future funding requirements depend heavily on YUTREPIA's sustained revenue generation.
Material Risks and Contingencies:
- United Therapeutics Litigation: The company faces multiple lawsuits from United Therapeutics alleging patent infringement (specifically the '327 and '782 patents) and trade secret misappropriation. United Therapeutics is seeking injunctive relief that could require YUTREPIA to be removed from the market or have the PH-ILD indication removed from its label. Trial for the '327 patent litigation was held in June 2025, with a decision pending.
- Supply Chain Constraints: Sales of Treprostinil Injection are constrained by the limited availability of the CADD-MS 3 infusion pump, which is no longer manufactured by ICU Medical. The company is working to identify replacement pumps but faces regulatory clearance hurdles.
- Debt Covenants: The company has a revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR) requiring a minimum cash balance of $15.0 million. As of March 31, 2026, the company is in compliance.
Investor Verification Checklist
- Verify the status and potential outcome of the pending '327 Patent Litigation decision, as an adverse ruling could force YUTREPIA off the market.
- Confirm the timeline for FDA clearance of replacement infusion pumps for Treprostinil Injection to assess the sustainability of service revenue.
- Monitor the company's ability to maintain the $15.0 million minimum cash covenant under the HCR Agreement amidst ongoing litigation costs and commercialization expenses.
- Review the progress of the L606 pivotal clinical trial for PH-ILD, which is a key future growth driver.
- Assess the concentration risk in accounts receivable, noting that two customers accounted for 86% of gross product sales in Q1 2026.